The strategic role of the medical physicist and the production of radiopharmaceuticals: fundamentals, regulation, and pathways for the expansion of Brazilian Nuclear Medicine
DOI:
https://doi.org/10.29384/rbfm.2026.v20.19849001908Keywords:
Nuclear Medicine, Medical Physics, Radiopharmaceuticals, Radiopharmacy, Precision Medicine, TheranosticsAbstract
Nuclear Medicine (NM) has undergone a profound transformation driven by advances in radiopharmaceutical
production, molecular imaging, theranostics, and personalized dosimetry. In Brazil, however, the sustainable
expansion of NM remains constrained by structural challenges involving production capacity, regulatory
complexity, logistics, technological incorporation, and unequal regional access. This narrative review critically
analyzes the Brazilian radiopharmaceutical production chain, emphasizing the strategic role of the medical
physicist in integrating scientific knowledge, technological innovation, regulatory compliance, and clinical
practice. A qualitative review of scientific literature, textbooks, institutional reports, and national and international
regulatory documents was conducted using major databases and official repositories. The analysis
demonstrates that the expansion of NM requires a systemic approach combining resilient production
infrastructure, risk-based regulation, decentralized production models, qualified logistics, and coordinated
governance. Particular attention is given to advances in cyclotron technology, radionuclide generators,
therapeutic radioisotopes, alpha-emitting radionuclides, predictive dosimetry, and conceptual operational
models for decentralized radiopharmaceutical production. The review also discusses how the medical physicist
has evolved beyond traditional responsibilities in radiation protection and quality control to become a strategic
professional involved in production planning, process validation, dosimetry, regulatory implementation,
innovation, and healthcare system development. The findings indicate that strengthening the integration
between production, regulation, logistics, and clinical application is essential to improve equitable access to
Nuclear Medicine in Brazil. The medical physicist is therefore positioned as a key stakeholder in building a safe,
innovative, and sustainable national NM infrastructure capable of supporting future advances in precision
medicine.
Downloads
References
1. Cherry SR, Sorenson JA, Phelps ME. Physics in Nuclear Medicine. 4th ed. Philadelphia: Elsevier Saunders; 2012.
2. Ziessman HA, O’Malley JP, Thrall JH, editors. Nuclear Medicine: The Requisites. 4th ed. Philadelphia: Elsevier Saunders; 2014.
3. International Atomic Energy Agency. Operational guidance on hospital radiopharmacy: a safe and effective approach. Vienna: IAEA; 2008.
4. Imam SK. Molecular nuclear imaging: the radiopharmaceuticals. Cancer Biother Radiopharm. 2005;20(2):163-72.
5. Santos-Oliveira R, Carneiro-Leão AMA. História da radiofarmácia e as implicações da Emenda Constitucional n. 49. Rev Bras Cienc Farm. 2008;44(3):377-82.
6. Pozzo L, Coura Filho G, Osso Júnior JA, Squair PL. O SUS na medicina nuclear do Brasil: avaliação e comparação dos dados fornecidos pelo Datasus e CNEN. Radiol Bras. 2014;47(3):141-8.
7. Baffa O, Araújo DB de. Um panorama da física médica. In: Ciências físicas no Brasil. São Paulo: Livraria da Física; 2006.
8. Brasil. Autoridade Nacional de Segurança Nuclear. Norma CNEN NN 5.01: regulamento para o transporte seguro de materiais radioativos. Rio de Janeiro: CNEN; 2021.
9. International Atomic Energy Agency. Cyclotron produced radionuclides: guidance on facility design and production of [18F]Fluorodeoxyglucose (FDG). Vienna: IAEA; 2012.
10. Brasil. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada – RDC nº 738, de 28 de julho de 2022. Dispõe sobre o registro, notificação, importação e controle de qualidade de radiofármacos industrializados. Diário Oficial da União; 1 ago 2022.
11. Brasil. Agência Nacional de Vigilância Sanitária. Instrução Normativa nº 128, de 30 de março de 2022. Dispõe sobre as Boas Práticas de Fabricação complementares a Medicamentos Radiofármacos. Diário Oficial da União; 31 mar 2022.
12. Brasil. Autoridade Nacional de Segurança Nuclear. Norma ANSN 6.13: requisitos de segurança e proteção radiológica em instalações de radiofarmácias centralizadas e industriais. Rio de Janeiro: CNEN; 2022.
13. Brasil. Autoridade Nacional de Segurança Nuclear. Norma CNEN NN 6.11: requisitos de segurança e proteção radiológica em instalações produtoras de radioisótopos com aceleradores cíclotrons. Rio de Janeiro: CNEN; 2020.
14. United States. Food and Drug Administration. 21 CFR Part 212: current good manufacturing practice for positron emission tomography drugs. Silver Spring: FDA; 2009.
15. Brasil. Autoridade Nacional de Segurança Nuclear. Norma ANSN 3.05: requisitos de segurança e proteção radiológica para serviços de medicina nuclear. Rio de Janeiro: CNEN; 2013.
16. Brasil. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada – RDC nº 658, de 30 de março de 2022. Dispõe sobre as Diretrizes Gerais de Boas Práticas de Fabricação de Medicamentos. Diário Oficial da União; 31 mar 2022.
17. Brasil. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada – RDC nº 488, de 7 de abril de 2021. Dispõe sobre a importação de produtos sujeitos à vigilância sanitária por unidade de saúde, para seu uso exclusivo. Diário Oficial da União; 8 abr 2021.
18. Brasil. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada – RDC nº 67, de 8 de outubro de 2007. Dispõe sobre Boas Práticas de Manipulação de Preparações Magistrais e Oficinais para Uso Humano em farmácias. Diário Oficial da União; 9 out 2007.
19. Elsinga P, Todde S, Penuelas I, Meyer G, Farstad B, Faivre Chauvet A, et al. Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2010;37(5):1049-62.
20. Pharmaceutical Inspection Co-operation Scheme. Guide to Good Manufacturing Practice for Medicinal Products: PE 00917. Geneva: PIC/S; 2023.
21. International Council for Harmonisation. ICH Q9(R1): quality risk management. Geneva: ICH; 2023.
22. International Council for Harmonisation. ICH Q10: pharmaceutical quality system. Geneva: ICH; 2008.
23. Pharmaceutical Inspection Co-operation Scheme. Recommendation on the validation of aseptic processes: PI 007-6. Geneva: PIC/S; 2011.
24. União Europeia. Directiva 2001/83/CE do Parlamento Europeu e do Conselho, de 6 de novembro de 2001, estabelece um código comunitário relativo aos medicamentos para uso humano. Bruxelas: UE; 2001.
25. Lee JS, Kim KM, Choi Y, Kim HJ. A brief history of nuclear medicine physics, instrumentation, and data sciences in Korea. Nucl Med Mol Imaging. 2021;55(6):265-84. doi:10.1007/s13139-021-00721-7.
26. Hu J, Li H, Sui Y, Du J. Current status and future perspective of radiopharmaceuticals in China. Eur J Nucl Med Mol Imaging. 2021:1-17. doi:10.1007/s00259-021-05615-6.
27. Grundler PV, Eichler R, Talip Z, Schubiger PA, Schibli R, van der Meulen NP. The metamorphosis of radionuclide production and development at Paul Scherrer Institute. Chimia. 2020;74(12):968-75. doi:10.2533/chimia.2020.968.
28. Sjögreen-Gleisner K, et al. EFOMP policy statement No. 19: dosimetry in nuclear medicine therapy - molecular radiotherapy. Phys Med. 2023. doi:10.1016/j.ejmp.2023.103166.
29. Scott A, et al. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics. Lancet Oncol. 2024;25(6):e250-9. doi:10.1016/S1470- 2045(24)00037-8.
30. Baberwal P, Basu S. Advances in functional radionuclide imaging and therapy for individualized management of patients: the growing importance of nuclear theranostics in precision oncology practice. Expert Rev Precis Med Drug Dev. 2025;10:56-74 doi:10.1080/23808993.2025.2589524.
31. Scott A, et al. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics. Lancet Oncol. 2024;25(6):e250-9. doi:10.1016/S1470-2045(24)00037-8.
32. Jacene HA, et al. Radiopharmaceutical therapy: rapid growth, rising challenges, and the critical need for expertise. J Nucl Med. 2025 Oct. doi:10.2967/jnumed.125.271028.
33. Urbain JL, et al. Theranostic radiopharmaceuticals: a universal challenging educational paradigm in nuclear Associação Brasileira de Física Médica ® medicine. J Nucl Med. 2023;64(6):986-91. doi:10.2967/jnumed.123.265603.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Héber S Videira, Dra, Dr., Sr., Dr., Dr., Dr., Lais Santos, Paulo Tarso, Moizes Filho

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The submission of original articles to the Brazilian Journal of Medical Physics implies the transfer, by the authors, of the rights of print and digital publication. Copyright for published articles remains with the author, with journal rights on first publication. Authors may only use the same results in other publications by clearly indicating this journal as the original publisher. As we are an open access journal, free use of articles in educational, scientific, non-commercial applications is allowed, as long as the source is cited.
The Brazilian Journal of Medical Physics is under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).


